Lucentis for Central Retinal Vein Occlusion (CRVO)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ranibizumab will be effective in reducing
if not eliminating the macular edema associated with the disease, central retinal vein
occlusion (CRVO).